arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 7/2023 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    NEW ON THE MARKET

    First Rho kinase inhibitor for glaucoma: netarsudil (in ROCLANDA)

    a-t READERS QUESTIONS AND COMMENTS

    Hepatitis B vaccine HEPLISAV B

    FAST trial: gout medication febuxostat (ADENURIC, generics) rehabilitated?

    Does daily intake of vitamin D reduce cancer mortality?

    THERAPY FROM A CRITICAL VIEWPOINT

    WHO advises not to use non-sugar sweeteners

    BEWARE MISINFORMATION

    Misleading advertisement for desvenlafaxine (DESVENEURAX)
    free

    IN BRIEF

    Deutsches Ärzteblatt adheres to advertising column “PHARMA”

    Clinical trials – improvement required concerning endpoints and registration

    Youth protection: need for action regarding e-cigarettes

    e a-t ON THE INTERNET

    First Rho kinase inhibitor for glaucoma: netarsudil (in ROCLANDA) (long version)

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles

    Wir schätzen Ihr Feedback

    Nehmen Sie an unserer Umfrage teil!